Minocycline in Neurocognitive Outcomes - Sickle Cell Disease

Launched by UNIVERSITY OF CINCINNATI · Oct 28, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called minocycline on cognitive decline in adults with sickle cell disease (SCD). Sickle cell disease can lead to issues with thinking, learning, and memory due to inflammation in the brain, even if there hasn’t been any obvious brain injury. The trial aims to find out how safe minocycline is and how well it might work to help prevent or improve these cognitive problems. Participants will take either minocycline or a placebo (a pill with no active medication) for one year, and their cognitive abilities will be assessed at the start and end of the study.

To be eligible for this trial, participants must be at least 18 years old and have specific types of sickle cell disease, as well as be receiving standard treatment with hydroxyurea. However, individuals with other types of sickle cell disease, a history of strokes, or certain other health conditions will not be able to participate. Throughout the study, participants can expect regular check-ins over the phone, visits every three months to monitor their health, and assessments to see how well they are doing with their thinking and memory. This trial is not yet recruiting participants, but it represents an important step in exploring new ways to support cognitive health in those living with sickle cell disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (age ≥ 18 years old) with SCD (HbSS and HbS-β0thalassemia genotypes only) who are followed at the University of Cincinnati Medical Center's SCD clinic are eligible to participate. As hydroxyurea is the standard-of-care in SCD, individuals on hydroxyurea will be included
• Exclusion Criteria:
• • 1. adults with other SCD genotypes (HbSC or HbS- β+thalassemia),
• • 2. individuals with a history of overt stroke or other known neurological disorder,
• • 3. premature birth before 30 weeks gestation,
• • 4. monthly therapy with chronic blood transfusions,
• • 5. coexisting autoimmune condition due to an elevated risk for autoimmune-related complications with tetracyclines,
• • 6. tetracycline allergy.
• • 7. Women who are pregnant or breast-feeding